US Oncology Research Network Presents Clinical Studies at San Antonio Breast Cancer... (osphamide 500 mg/m2 all IVevery 21 D x 4...)

US Oncology Research Network Presents Clinical Studies at San Antonio Breast Cancer Symposium

Date:12/17/2007

osphamide 500 mg/m2 all IV every 21 D x 4 cycles. Post ASCO '05, HER2+ pts received H (4 mg/kg on Day 1, then 2 mg/kg wkly x 12 wks).

After FEC, weekly docetaxel with capecitabine (wTX), both given every 21 D x 4 as: docetaxel 35 mg/m2 on D1 & D8, capecitabine 825 mg/m2 PO BID D1-14; and, if HER2+, H given as in part I. After CT, definitive local therapy (mastectomy or lumpectomy & axillary dissection) was done.

The research findings indicated that 185 patients with a median age of 50 years (range, 24-84) were treated; 179 underwent definitive surgery. Results are summarized in the table below:

Subset Number of Patients Percentage pCR

Breast/Ax

All patients with surgery

post CT 179 34 (27-41)

ER or PR+ HER2- 80 24 (16-34)

FR-, PR-, HER2- 63 23 (31-55)

HER2-, no H 143 32 (25-40)

HER2+, received FEC 75+H 36 39 (25-55)

The most frequent Grade 3-4 toxicities were neutropenia (77 percent), diarrhea (9 percent), hand-foot syndrome (8 percent), and stomatitis (7 percent).

Decreased left ventricular ejection fraction (LVEF) <50 percent occurred in 4 of 40 pts receiving FEC75+H but there was no heart failure & repeat LVEFs were >50 percent in all 4 patients.

Of 143 non-H treated patients, two had LVEFs <50 percent (one each: 25 percent, 44 percent). Microarray: 107/192 specimens generated less than or equal to 10 mcg cRNA, median 35 mcg, which was hybridized to Affymetrix HG- U133A gene chips successfully in 101 specimens. The success rate was 35 percent in the first 80 cases and 65 percent in the last 112 cases. Sample attrition precluded separate discovery/validation cohorts so data combined with two MDA
'/>"/>

13

GOOD

Page: 1 2 3 4
Related medicine technology :

1. Paper in International Journal of Oncology Reports Alfacells ONCONASE(R) Suppresses Intracellular Oxidative Stress
2. HistoRx and Radiation Therapy Oncology Group Initiate Brain Tumor Biomarker Research Partnership
3. Genasense(R) Data in Melanoma to be Presented in Opening Session at First Worldwide Melanoma Center Meeting of the European Association of Dermato-Oncology
4. Oncology Drugs Development Update - Worldwide Markets and Forecasts of Approved EGFr/HEr2 Inhibitors, Treatment Costs, Pathway Analysis, Current and Expanded Clinical Indications, and Novel Agents in Development
5. Strategic Diagnostics Launches Initial Oncology-Targeted Antibody Reagent Catalog
6. University of Pennsylvania School of Medicine Study Shows Significant Differences in English- and Spanish-speakers Use of Oncology Websites
7. Statement by US Oncology on FDA Label on Erythropoiesis Stimulating Agents (ESAs)
8. Pharsight Uses FDA Disease Model to Support Oncology Drug Development
9. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
10. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
11. Lexicon to Present Research Results at American Chemical Society Meeting Regarding Target of LX1031 Drug Candidate

Post Your Comments:

US Oncology Research Network Presents Clinical Studies at San Antonio Breast Cancer...(osphamide 500 mg/m2 all IVevery 21 D x 4...),Health